Exelixis
EXEL
$21.00
Share price
-0.57%
Change (1 day)
7.69%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Exelixis (EXEL) - P/B ratio
P/B ratio as of May 2024 : 2.89
According to Exelixis's latest financial reports the company has a price-to-book ratio of 2.89.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Exelixis - P/B ratio (from 2001 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 3.30 | 58.49% |
| 2022-12-31 | 2.08 | -20.53% |
| 2021-12-31 | 2.62 | -21.04% |
| 2020-12-31 | 3.31 | 4.35% |
| 2019-12-31 | 3.18 | -30.69% |
| 2018-12-31 | 4.58 | -85.48% |
| 2017-12-31 | 31.6 | -34.79% |
| 2016-12-31 | 48.4 | -630.03% |
| 2015-12-31 | -9.13 | 271.69% |
| 2014-12-31 | -2.46 | -114.38% |
| 2013-12-31 | 17.1 | 503.03% |
| 2012-12-31 | 2.83 | -60.01% |
| 2011-12-31 | 7.08 | -280.23% |
| 2010-12-31 | -3.93 | -19.11% |
| 2009-12-31 | -4.86 | -48.44% |
| 2008-12-31 | -9.42 | -189.13% |
| 2007-12-31 | 10.6 | 10.87% |
| 2006-12-31 | 9.53 | -30.47% |
| 2005-12-31 | 13.7 | -2.47% |
| 2004-12-31 | 14.1 | 351.72% |
| 2003-12-31 | 3.11 | 15.26% |
| 2002-12-31 | 2.70 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.25 | 81.51% | 🇺🇸 USA |
 Pfizer PFE | 1.83 | -36.73% | 🇺🇸 USA |
 Amgen AMGN | 27.5 | 849.92% | 🇺🇸 USA |
 Sanofi SNY | 1.50 | -47.96% | 🇫🇷 France |
 Merck MRK | 8.87 | 206.65% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 5.46 | 88.77% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 5.64 | 94.97% | 🇬🇧 UK |
 Curis CRIS | 3.90 | 34.74% | 🇺🇸 USA |
 AVEO Oncology
AVEO | 18.1 | 525.30% | 🇺🇸 USA |